ALX ONCOLOGY HLDGS INC's ticker is ALXO and the CUSIP is 00166B105. A total of 58 filers reported holding ALX ONCOLOGY HLDGS INC in Q3 2020. The put-call ratio across all filers is - and the average weighting 2.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,839,533 | -36.0% | 1,008,236 | +0.2% | 0.00% | – |
| Q2 2023 | $7,559,476 | +61.5% | 1,006,588 | -2.8% | 0.00% | – |
| Q1 2023 | $4,680,637 | -70.9% | 1,035,539 | -27.3% | 0.00% | – |
| Q4 2022 | $16,063,109 | +19.0% | 1,425,298 | +1.0% | 0.00% | – |
| Q3 2022 | $13,503,000 | +26.0% | 1,411,009 | +6.5% | 0.00% | – |
| Q2 2022 | $10,717,000 | -62.2% | 1,324,737 | -20.9% | 0.00% | -100.0% |
| Q1 2022 | $28,318,000 | -22.8% | 1,675,656 | -1.9% | 0.00% | 0.0% |
| Q4 2021 | $36,705,000 | -70.4% | 1,708,034 | +1.7% | 0.00% | -66.7% |
| Q3 2021 | $124,049,000 | +46.4% | 1,679,528 | +8.4% | 0.00% | +50.0% |
| Q2 2021 | $84,738,000 | -15.3% | 1,549,718 | +14.2% | 0.00% | -33.3% |
| Q1 2021 | $100,074,000 | +31.4% | 1,357,108 | +53.6% | 0.00% | +50.0% |
| Q4 2020 | $76,136,000 | +212.6% | 883,262 | +36.9% | 0.00% | +100.0% |
| Q3 2020 | $24,357,000 | – | 645,382 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| venBio Partners LLC | 9,699,925 | $163,929,000 | 36.34% |
| Logos Global Management LP | 3,011,352 | $50,892,000 | 6.60% |
| Vivo Capital, LLC | 4,220,048 | $71,319,000 | 4.91% |
| Samsara BioCapital, LLC | 262,786 | $4,441,000 | 1.12% |
| Cormorant Asset Management, LP | 712,079 | $12,034,000 | 0.92% |
| Pier Capital, LLC | 394,443 | $6,666,000 | 0.85% |
| Redmile Group, LLC | 772,397 | $13,054,000 | 0.41% |
| Artal Group S.A. | 500,000 | $8,450,000 | 0.35% |
| Nan Fung Group Holdings Ltd | 41,950 | $709,000 | 0.34% |
| Orbimed Advisors | 621,700 | $10,507,000 | 0.17% |